Companies /Healthcare

CapsoVision, Inc. Common Stock

NASDAQ: CV Medical Devices
$6.47
▲ $0.44 (+7.30%) today
Markets closed · 7:54pm ET

CV at a Glance

Valuation
Market cap
$323.3M
Profitability
Revenue (TTM)
$13.9M
Profit margin
-210.1%
EPS (TTM)
$-0.42
Price
52-week range
$5 – $15
Street target
$9.50

Headquartered in Saratoga, CA Fiscal year ends December NASDAQ: CV capsovision.com

About CapsoVision

CapsoVision, Inc. is a commercial-stage medical technology company that develops advanced imaging and AI-enabled capsule endoscopy systems for detecting and screening gastrointestinal diseases. Its flagship commercial product, CapsoCam Plus, is a wire-free capsule endoscope with four cameras that gives a 360-degree panoramic view of the small bowel. Physicians can review the capsule video through cloud-based or direct capsule review. As of September 30, 2026, more than 184,000 patients worldwide had used CapsoCam Plus. In September 2026 the company received FDA clearance for AI Highlights, an AI-assisted reading tool for CapsoCam Plus cleared for adults and children aged two and older. It launched AI Highlights commercially in the U.S. in November 2026. The next pipeline product is CapsoCam Colon, a second-generation capsule with enhanced AI for non-invasive colon imaging and polyp detection. Its pivotal study is complete and a 510(k) submission is targeted for year-end 2026. The company is also developing CapsoCam UGI for upper GI indications, including a clinical study in pancreatic cancer (PDAC) detection, as part of a proprietary platform it aims to extend to esophageal and pancreatic disorders. CapsoVision funds operations through equity, including registered direct offerings and an at-the-market program. Updated

CV Coverage

Frequently Asked Questions

What does CapsoVision do?

CapsoVision, Inc. is a commercial-stage medical technology company that develops advanced imaging and AI-enabled capsule endoscopy systems for detecting and screening gastrointestinal diseases.

What is the CV stock price target?

The Wall Street consensus 12-month price target for CV is $9.50.